Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bally

Showing results (151-160 of 225) with videos related to

Pageof 23
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1989
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicinJ A Balazsovits, L D Mayer, M B Bally, et al.
Cancer Research|November 1, 1989
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in miceL D Mayer, L C Tai, D S Ko, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injectionL Embree, K Gelmon, A Tolcher, et al.
Bioconjugate Chemistry|March 1, 1995
Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomesT O Harasym, P Tardi, S A Longman, et al.
BMC Cancer|April 12, 2011
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineMaite Verreault, Dita Strutt, Dana Masin, et al.
Nanomedicine (London, England)|October 21, 2011
Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activityJesse Popov, Anita I Kapanen, Christopher Turner, et al.
Oncogene|September 15, 2010
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1J Kalra, B W Sutherland, A L Stratford, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancerM S Webb, P Logan, P M Kanter, et al.
Magnetic Resonance in Medicine|June 2, 2004
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted deliveryBenjamin L Viglianti, Sheela A Abraham, Charles R Michelich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumorsEuan C Ramsay, Malathi Anantha, Jason Zastre, et al.
Pageof 23

Showing results (151-160 of 225) with videos related to

Sort By:
Pageof 23
Cancer Chemotherapy and Pharmacology|January 1, 1989
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicinJ A Balazsovits, L D Mayer, M B Bally, et al.
Cancer Research|November 1, 1989
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in miceL D Mayer, L C Tai, D S Ko, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injectionL Embree, K Gelmon, A Tolcher, et al.
Bioconjugate Chemistry|March 1, 1995
Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomesT O Harasym, P Tardi, S A Longman, et al.
BMC Cancer|April 12, 2011
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineMaite Verreault, Dita Strutt, Dana Masin, et al.
Nanomedicine (London, England)|October 21, 2011
Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activityJesse Popov, Anita I Kapanen, Christopher Turner, et al.
Oncogene|September 15, 2010
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1J Kalra, B W Sutherland, A L Stratford, et al.
Cancer Chemotherapy and Pharmacology|October 27, 1998
Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancerM S Webb, P Logan, P M Kanter, et al.
Magnetic Resonance in Medicine|June 2, 2004
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted deliveryBenjamin L Viglianti, Sheela A Abraham, Charles R Michelich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumorsEuan C Ramsay, Malathi Anantha, Jason Zastre, et al.
Pageof 23